Phillip Frost, CEO & Chairman of Opko Health Inc. (NASDAQ:OPK) Just Acquired Shares

Phillip Frost Insider Buy

Director Phillip Frost of Opko Health Inc, bought 5,400 of the firm shares worth $59,448 US Dollars with an average of $11.0 per share. He also purchased 46,200 shares that are worth approx $460,341 USD in the last 30 days. Now, he owns a total of 183.32 million shares or 34.30% of Opko Health Inc’s market cap.

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.16, from 0.84 in 2016Q1. The ratio improved, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.

Oracle Investment Management Inc holds 8.51% of its portfolio in Opko Health Inc. for 3.91 million shares. Rk Asset Management Llc owns 922,617 shares or 7.7% of their US portfolio. Moreover, Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management) has 2.4% invested in the company for 3.12 million shares. The Israel-based Menora Mivtachim Holdings Ltd. has invested 1.6% in the stock. Weiss Multi, a Alabama-based fund reported 1.81 million shares.

The stock decreased 2.86% or $0.32 during the last trading session, hitting $10.87. Opko Health Inc. (NASDAQ:OPK) has risen 18.93% since February 25, 2016 and is uptrending. It has outperformed by 7.67% the S&P500.

OPKO Health, Inc. is a healthcare company. The company has a market cap of $6.05 billion. The Firm operates through two divisions: diagnostics and pharmaceutical. It has a 41.84 P/E ratio. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations.

According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”

Analysts await Opko Health Inc. (NYSE:OPK) to report earnings on November, 14. They expect $-0.03 earnings per share, down 112.00% or $0.28 from last year’s $0.25 per share. After $0.02 actual earnings per share reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts -250.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment